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Abstract: The histologically defined tumor entity glioblastoma (GBM) comprises different molecular subgroups. On a 
transcriptional level, at least two subgroups were uniformly identified: proneural and mesenchymal GBM. Treatment 
of GBM with radiotherapy and anti-angiogenic drugs may trigger molecular subtype transformation with proneural 
tumors shifting towards a mesenchymal phenotype. Because both treatment modalities also result in dramatic 
changes of the metabolic microenvironment of GBM, we hypothesized if the major determinants in local microen-
vironment-hypoxia and (lactate) acidosis-may induce consistent changes in the phenotype of primary glioblastoma 
stem cell lines in vitro. A panel of 5 different proneural GBM stem cell lines (GSC) lines was systematically chal-
lenged for 7 days with acidosis (pH 5.5-7.4), sodium lactate (0-60 mM), lactic acid (0-15 mM), or with 72 h hypoxia 
(2% oxygen). Acidosis significantly improved survival but inhibited proliferation of GSC lines. Sodium lactate inhibited 
proliferation without affecting survival. Neither acidosis nor sodium lactate did consistently change growth pattern 
or stem cell marker expression. Hypoxia and lactate induced a more proneural-like phenotype with increased Olig2 
and CD133 expression in 1 GSC line, but did not consistently alter marker expression in the other 4 GSC lines. None 
of the 5 GSC lines investigated showed changes indicative for a proneural-to-mesenchymal transformation towards 
a more malignant phenotype. Taken together, our data does not exclude the possibility that metabolic factors like 
lactate acidosis may induce a more mesenchymal phenotype. Nevertheless, data suggest that therapy-induced 
metabolic changes in the microenvironment are likely not of crucial importance to our understanding of mesenchy-
mal transformation after radio-and anti-angiogenic therapy for most GBM.
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Introduction
Glioblastoma (GBM) is the most common pri-
mary malignant brain tumor with an average 
survival of affected patients of about 15 
months [1]. All GBM share same histological 
features but differ substantially on a molecular 
level. Various attempts have been made to 
divide GBM into different groups based on their 
profile on mRNA, protein, genome, and stem 
cell level [2-7]. Although all studies varied with 
respect to their results and the number of sub-
groups identified, all studies agreed on the exi- 
stence of two major groups: a (pro-) neural and 
a mesenchymal phenotype, which account for 
the majority of all GBM. These two groups were 
initially named because of the expression of 
marker genes resembling different stages of 
neurogenesis [3]. The subtypes differ substan-
tially with respect to tumor cell properties (e.g. 
differences in WNT-, TGF-beta, hippo-signaling) 
but possibly also with respect to local microen-
vironment, amongst others extend of immune 
infiltration [8, 9]. It remains controversial if both 
subgroups have prognostic significance for 
patients treated with standard therapy [3, 7, 
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10]. Differences of both groups in response to 
immunotherapy have, though, been observed 
[11]. 
GBM are characterized by massive angiogene-
sis, and new antiangiogenic therapies raised 
hopes to improve the patients’ outcome. 
Glioma-induced angiogenesis can be visualized 
using MRI as tumor core with pathological 
blood vessels and contrast enhancement [12-
15]. The most thoroughly investigated sub-
stance-bevacizumab (BEV)-induces often a 
dramatic response of the contrast-enhancing 
tumor in MRI and substantially improves the 
progression free survival (PFS) of patients irre-
spective of the molecular subtype [13, 16, 17]. 
However, BEV failed in recent clinical studies to 
improve overall survival [16]. The combination 
of an impressive improvement of PFS without 
improvement in overall survival suggests a 
malignant transformation of the tumor under 
therapy. This malignant transformation seems 
to depend on the molecular subtype: a retro-
spective analysis of the AVAGlio [16] data could 
recently show, that tumors with a mesenchymal 
subtype did not benefit from BEV treatment, 
while patients with proneural GBM did [17].
If and how a transformation of the molecular 
phenotype influences these differences re- 
mains controversial. Piao et al. showed data 
suggesting that treatment failure after BEV 
may be caused by a proneural-to-mesenchymal 
transformation [18]. A molecular analysis of the 
molecular phenotypes by DeLay et al. before 
and after therapy showed transition of the phe-
notype after BEV treatment in 8 of 13 tumors 
investigated [19]. However, they found a BEV 
induced a transformation in both directions (i.e. 
proneural-to-mesenchymal and vice versa). A 
transformation of the molecular phenotypes 
was also described for recurrent gliomas after 
radiotherapy by Phillips et al.: 8 out of 26 paired 
samples investigated changed the molecular 
phenotype mainly from a proneural to a mesen-
chymal profile [3]. In conclusion, these and 
other reports [20] support the hypothesis that 
a transformation of the molecular subtype may 
contribute to treatment failure.
Treatment with BEV and radiotherapy results 
in relevant changes of the important determi-
nants of the metabolic microenvironment [21]. 
Impairing and destroying tumor angiogene- 
sis results in tissue hypoxia, increased glycoly-
sis, and lactate acidosis. Conversely, metabolic 
changes have been postulated determinants of 
treatment failure/success under BEV treat-
ment [22]. It is therefore possible that these 
factors may be the crucial trigger for this trans-
formation of the molecular phenotype.
GSC lines became an accepted and widely 
used in vitro model to investigate GBM biology. 
GSC lines are more favorable compared to 
serum-cultured cell lines because they are 
genetically stabile and closely resemble the ini-
tial tumor also after many passages in vitro 
[23]. Like GBM, GSC lines derived from tumors 
are heterogeneous, and, as in the parental 
tumors, GSC lines with a proneural and a 
mesenchymal transcription profile have been 
described [6, 8, 24]. Both types of GSC differ 
with respect to marker expression, although, to 
date, no unambiguous marker for the two major 
subtypes has been identified. Recently, several 
studies independently suggested CD133 and 
CD44 as markers for proneural and mesenchy-
mal GSC [6, 25, 26]. In vivo, Olig2 and DLL3 
have been proposed to be indicative for pro-
neural and YKL-40 for mesenchymal GBM [3, 
8]. In vitro, these GSC lines may differ with pro-
neural GSC showing a neurosphere-like growth 
pattern and mesenchymal GSC having a more 
adherent growth pattern [24, 27]. However, the 
analysis of the growth pattern is not without 
ambiguity because culture conditions (e.g. con-
tinuous selection of spheres, laminin coating, 
or frequent use of trypsin) change the growth 
pattern without affecting the molecular sub- 
type. 
The molecular mechanisms of transformation 
from a proneural to a more mesenchymal phe-
notype were recently investigated using GSC 
lines. These studies showed that alterations 
of TGF-beta [8, 28-30], TNF-alpha/NFkB, and 
MET-signaling [31, 32] were of importance 
especially for proneural-to-mesenchymal trans-
formation. The putative mechanisms of the 
mesenchymal-to-proneural transformation af- 
ter BEV treatment are to date unknown.
In contrast to in vivo studies, the study of GSC 
allows to investigate changes in the tumor cells 
only. This is relevant because invading neural 
stem cells or mesenchymal cells may substan-
tially modulate the molecular phenotype of 
tumor samples without a relevant change of 
bona fide tumor cells. We therefore used a 
panel of GSC lines to address the question if 
metabolic challenge induces a proneural-to-
Metabolic challenge of glioblastoma stem cell lines
6726 Int J Clin Exp Pathol 2016;9(7):6724-6737
mesenchymal transformation in proneural GSC 
lines to substantiate or to falsify the hypothesis 
that metabolic changes may induce a mesen-
chymal transformation of GBM cells. 
Materials and methods
Cell culture
All GSC lines were derived from primary tumor 
tissue dissociated direct after operation as 
described previously [24, 33]. All primary 
tumors were IDH wildtype GBM diagnosed 
according to the WHO classification [34]. The 
generation of GSC was approved by the local 
Ethic Committees of Southern Denmark and at 
the University Hospital Regensburg. GSC lines 
were cultured in DMEM-F12 supplemented 
with 20 ng/ml EGF, 20 ng/ml bFGF, B27 (1:50), 
and antibiotics as described previously [6, 24].
Microarray analysis
Microarray analyses were previously described 
in [6, 24, 35]. In brief, total RNA was isolated 
using the Qiagen RNeasy kit. The generation 
of labeled cRNA and its hybridization to U133 
Plus 2 GeneChip arrays (Affymetrix) were done 
and scanned at the Kompetenzzentrum für 
Fluoreszente Bioanalytik (KFB; Regensburg, 
Germany) and the Department of Clinical 
Genetics (Odense University Hospital, Odense, 
Denmark) according to standard procedures 
[24]. Analyses were performed using BRB-Array 
Tools developed by Dr. Richard Simon and 
BRB-Array Tools Development Team. Additional 
microarrays of established GSC lines and pub-
lished by Gunter et al. [27] and Lottaz et al. [6] 
were used for analysis. Arrays were normalized 
using RMA. Supervised clustering was per-
formed using the 24 genes signature published 
by Lottaz et al. [6].
Metabolic challenge
Acidosis: To induce acidosis, DMEM-F12 medi-
um was acidified using 37% HCl until the pH 
given was reached. For the experiments, the 
growth factors 20 ng/ml EGF, 20 ng/ml bFGF, 
B27 (1:50), and antibiotics were added. 
Lactate acidosis: For lactate acidosis, sodium 
lactate was treated with equimolar concentra-
tions of HCl resulting in lactic acid and NaCl. 
Lactic acid was added to standard culture 
medium to a final concentration of 5 and 15 
mM. 
Sodium lactate: Sodium lactate was added to 
standard culture medium in the concentrations 
given in the experiments. Due to the high con-
centrations used (up to 60 mM) we chose to 
use glucose to as control for osmolality.
Hypoxia: GSC lines were cultured as small 
spheres in T25 flasks. They were cultured under 
moderate hypoxia (2% O, 5% CO2, 94% N2) in a 
Sanyo O2/CO2 incubator (Sanyo Electric Co. 
Ltd., Japan) for 24 h and 72 h. After the treat-
ment the cells were re-seeded as single cells in 
6-well plates in pairs (20.000 in each well in 
the case of R28 24 h and 50.000 for the rest). 
After 3 and 7 days pictures were taken and the 
media was changed. 
Flow cytometry
Flow cytometry was performed according stan-
dard protocols. At the time points indicated, 
cells were trypsinized and harvested as single 
cells for cytometric analysis. Each sample/
treatment was split into 3 FACS samples for 
Isotype control (mIgG2b-PE, 1:100), CD133CD- 
133/2-PE (1:100, Miltenyi Biotech), and CD44-
FITC (1:100, BD), and PI staining (Sigma Aldrich). 
10.000 single cells were counted for each sam-
ple in a FACS Canto analyzer and the data were 
analyzed using FACS Diva software.
Western blot
Western blot was performed according to stan-
dard protocols. At the time points indicated, 
cells were harvested and total protein lysates 
were made using Cell Lysis Reagent (Sigma) 
containing both Protease Inhibitor Cocktail Set 
I and Phosphatase Inhibitor Cocktail Set II 
(Calbiochem). The extracts were separated by 
SDS-PAGE (4-12% Bis-Tris-gel, Novex) and 
transferred to a 0.45 µm PVDF membrane 
(Invitrogen). The Novex Sharp Pre-stained pro-
tein standard was used to assess the protein 
size. The primary antibodies used were anti-
YKL-40 (Quidel, 1:100), anti-Olig2 (Bio Labs 
1:100), and β-actin (N-term, AC-15 Sigma 
1:10.000). The secondary antibodies were rab-
bit IgG HRP-conjugated (Olig2, YKL-40) and 
mouse IgG HRP-conjugated (β-actin). 
Results
Characterization of the GSC lines
All GSC lines used were previously character-
ized in detail [6, 24, 35]. We recently could 
show that GSC can be classified as “proneural-
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like” and “mesenchymal-like” using a 24-gene 
signature [6]. Supervised clustering of mRNA 
expression profile of the 5 GSC lines used and 
a panel of 20 previously characterized GSC 
lines showed that all GSC lines were classified 
as “proneural-like” based on these signature 
genes (Figure 1). With respect to marker 
expression, 4 out of the 5 GSC lines expressed 
the surface epitope CD133, and all GCS lines 
expressioned the transcription factor Olig2, 
which are both marker proteins associated with 
Figure 1. Classification of previously published GSC lines by Gunther et al. [27], Lottaz et al. [6], and the GSC lines 
used (marked in yellow) according to the “Lottaz signature”. 
Table 1. Marker profile
CD133 Olig2 CD44 YKL-40
R28 +++ ++ - ++
T78 ++ +++ ++ -
T86 + ++ ++ +
T87 - +++ + +
T111 (+) + ++ ++
+++>50% positive cells/very strong signal WB; ++10-
50% positive cells/strong signal WB; +1-10% positive 
cells/weak signal WB; (+) 0.1-1% positive cells/very 
weak signal WB.
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“proneural-like” GSC [6, 25]. However, 4 out of 
5 GCS lines also expressed CD44, and 2 out of 
5 were positive for YKL-40, which are both 
putative markers for “mesenchymal-like GSC”. 
Table 1 gives and overview over the marker pro-
file of the GSC lines investigated.
Effects of low pH on 5 GSC lines
Low pH (due to lactate acidosis) and low oxygen 
pressure/tissue hypoxia are the major compo-
nents of the cellular metabolic microenviron-
ment and are closely related. We therefore 
Figure 2. Effects of acidosis on proliferation, survival, CD133/CD44 expression, growth pattern. (A) Cell number; 
(B) Proportion of viable cells; (C) Proportion of CD133 expressing cells; and (D) proportion of CD44 expressing cells 
after treatment with ph 6.5 and pH 5.5 for 7 days are given; (E) Representative pictures of the growth pattern of 
GSC lines R28 are shown.
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investigated the effects of chronic expose with 
major metabolic determinants-acidosis, lactate 
concentration, lactate acidosis, and hypoxia-on 
survival, proliferation, and in vitro phenotype of 
a panel of 5 different GSC lines. To differentiate 
the effects of lactate acidosis and low pH, we 
Figure 3. Effects of sodium lactate on proliferation, survival, CD133/CD44 expression, growth pattern. (A) Cell num-
ber; (B) Proportion of viable cells; (C) Proportion of CD133 expressing cells; and (D) proportion of CD44 expressing 
cells after treatment with 30 mM Na-lactate and 60 mM sodium lactate for 7 days are given. Medium supplemented 
with 60 mM glucose was chosen as control condition; (E) Representative pictures of the growth pattern of GSC lines 
R28 are shown. 
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Figure 4. Effects of lactate acidosis on prolif-
eration, survival, CD133/CD44 expression, 
growth pattern, Olig2/YKL-40 expression. (A)
Cell number; (B) Proportion of viable cells; (C) 
Proportion of CD133 expressing cells; and 
(D) proportion of CD44 expressing cells after 
treatment with 5 mM and 15 mM lactate for 
7 days are given; (E) Representative pictures 
of the growth pattern of GSC lines R28 are 
shown; (F) Western blot for Olig2 and YKL-40 
expression of the panel of GSC lines treated 
with 15 mM lactate for 7 days (C = control, L 
= treatment with 15 mM lactate). 
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challenged the 5 GSC lines using standard 
serum free medium acidified using HCl to pH 
6.5 and 5.5 for 7 days. Acidification significant-
ly and dose-dependently reduced the prolifera-
Figure 5. Effects of acute hypoxia on proliferation, survival, CD133/CD44 expression, growth pattern. (A) Cell num-
ber; (B) Proportion of viable cells; (C) Proportion of CD133 expressing cells; and (D) proportion of CD44 expressing 
cells after treatment with 2% O2 for 72 h days are given; (E) Representative pictures of the growth pattern of GSC 
lines R28 are shown; (F) Western blot for Olig2 and YKL-40 expression of the panel of GSC lines treated with hypoxia 
(2% oxygen) for 72 h (c = control, H = hypoxia).
Metabolic challenge of glioblastoma stem cell lines
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tion of GSC lines (Figure 2A). Remarkably, acidi-
fication also increased survival as determined 
by a significantly increased proportion of viable 
cells as determined by PI staining (Figure 2B). 
Despite these marked effect, acidification did 
neither significantly changed expression of the 
surface marker of CD133 and CD44 (Figure 
2C, 2D), nor the growth pattern of the GSC lines 
(Figure 2E).
Effects of sodium lactate on 5 GSC lines
Lactate acidosis is a major contributor to 
the metabolic microenvironment especially in 
tumors. To dissect the effects of lactate alone 
and lactate acidosis, we treated the panel of 5 
GSC with increasing doses of sodium lactate. 
As expected, sodium lactate significantly inhib-
ited proliferation of GSC lines (Figure 3A) with-
out consistently affecting survival of the cells 
(Figure 3B). With respect to stem cell marker 
expression, sodium lactate did not induce sig-
nificant and consistent changes in the expres-
sion of CD133 and CD44 (Figure 3C, 3D). 
Further, the growth pattern of the GSC was 
unaffected (Figure 3E).
Effects of lactate acidosis on GSC lines
Due to the “Warburg effect”, lactate acidosis 
represents a hallmark of cancer and is also 
present in GBM [36-38]. In vitro, increasing 
doses of lactate acidosis did not elicit homoge-
neous effects in the 5 GSC lines screened. 
Proliferation was impaired in two GSC lines 
(T86, T78), which were also particular sensitive 
to lactate and acidosis induced growth inhibi-
tion (Figure 4A). The concentrations used for 1 
week (5 mM and 15 mM lactate) did not 
increase proliferation of a single GSC line and 
did not consistently affect survival (Figure 4A, 
4B). With respect to stem cell marker expres-
sion, lactate acidosis induced CD133 expres-
sion in the GSC line T78. The other GSC lines 
did not show a relevant change in proneural 
(CD133, Figure 4C) and mesenchymal (CD44, 
Figure 4D) marker expression. Growth pattern 
was slightly altered in one GSC line (T111) 
towards a more adherent growth pattern 
(Figure 4E). Because of the slight effects seen 
in these experiments, we performed confirma-
tory experiments investigating the expression 
of YKL-40 and Olig2 by Western blot. Both are 
proposed marker proteins for mesenchymal 
and proneural-like GSC lines. Lactate acidosis 
induced an increased Olig2 expression in the 
GSC line T78, which also showed an increase of 
CD133 expression, and in the GSC line R28, 
which did not show a relevant change of CD133 
expression. The expression level of YKL-40 was 
not substantially altered by lactate acidosis. 
Short-term and long-term effects of hypoxia on 
GSC lines
Hypoxia is the other determinant of the meta-
bolic microenvironment and the effects of 
hypoxia on GSC lines have been extensively 
studied [35, 39, 40]. For this experiment, GSC 
lines were incubated with 2% oxygen for 72 h 
and analyzed direct after exposure and 7 days 
after re-plating of treated cells. There were no 
consistent changes in all 5 GSC lines. Hypoxia 
foster proliferation in GSC lines R28, T78, and 
T86 as compared to control conditions, the 
proliferation of GSC T87 was impaired under 
hypoxia but cells recovered rapidly (Figures 5A, 
5B and 6A, 6B). Notably, 2% hypoxia did not 
induce cell death but seemed to have protec-
tive properties (Figure 5B). Only the phenotype 
of GSC line T111 was substantially altered: 72 
h hypoxia slightly reduced the number of cells 
but the cells kept proliferating substantially 
slower than control cells (Figures 5A, 6A). The 
reduced proliferation of GSC lines T111 was 
paralleled by a decrease of CD133 and an 
increased expression of CD44 but without a 
change of the growth properties, loss of Olig2 
expression or increase of YKL-40 expression 
(Figures 5C-F, 6C-E). In the other 4 GSC lines, 
hypoxia slightly increased the expression of 
CD133 in two GSC lines. Because of the effects 
seen in the GSC lines T111, we chose to study 
the expression of Olig2 and YKL-40 in all GSC 
lines upon hypoxia. Hypoxia substantially 
induced Olig2 expression in the GSC line T78 
and slightly increased Olig2 expression in R28 
[41]. With respect to YKL-40, an increase of the 
expression level was seen in R28, T78 showed 
minimal reduction (Figure 5F). 
Discussion
A substantial part of GBM patients showed 
shrinkage of the contrast-enhancing part of 
the tumor upon anti-angiogenic therapy. Un- 
fortunately, this did not translate into a longer 
survival and may change the tumors’ growth 
pattern [42]. These clinical phenomena, also 
seen with other anti-angiogenic treatments, 
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may suggest a fundamental change of tumor 
properties. Piao et al. postulated that a proneu-
ral-to-mesenchymal transformation causes the 
acquisition of a more mesenchymal phenotype 
and thereby contributes to the resistance 
against anti-angiogenic therapy [18, 43]. Given 
that the mesenchymal phenotype may also be 
associated with a worse prognosis [3], this 
mesenchymal transformation may explain the 
more aggressive behavior of recurrent GBM 
especially after anti-angiogenic treatment. 
Data by DeLay et al. could not support the con-
cept proposed by Piao et al. but the mesenchy-
mal signature of a tumor does not necessarily 
only depend on tumor cells but also on cells 
within the tumor stroma, like endothelial cells. 
In vitro, we could anecdotally observe a trans-
formation of the expression profile of long-term 
GSC lines (unpublished observation). We there-
fore aimed at establishing an in vitro model 
allowing investigating how metabolic factors 
modulate the properties of proneural GSC 
lines. We screened at total of 8 GSC lines, 5 
GSC lines were investigated extensively. We 
could not observe any evidence for a transfor-
mation into a more mesenchymal subtype. 
Thus, we would like to contribute to the ongoing 
discussion on the relevance and pathomecha-
nism of the postulated mesenchymal transfor-
mation, by providing evidence that chronic 
changes in the metabolic microenvironment 
were not able to induce a relevant mesenchy-
mal transformation in our panel of proneural 
GSC lines. Quite contrary to this hypothesis, we 
found a GSC line (T78), which showed a more 
proneural-like phenotype with induction of 
Olig2 and CD133 expression. We did not go 
into detail if this increase of marker expression 
actually corresponded to induction of “stem-
ness” or a more pronounced proneural pheno-
type. Either way there was no indication for a 
more mesenchymal phenotype. Furthermore, 
we did not make microarray analysis after met-
abolic challenge of the GSC lines. The analysis 
of the cell cultures did neither indicate a change 
of the growth pattern, nor a remarkable 
increase of migrating cells. Thus, microrarray 
analysis would not have contributed to our 
understanding of the lack of a mesenchymal 
transformation.
Of course, our experiment does not exclude the 
possibility that a proneural-to-mesenchymal 
transformation does exist. We could have used 
more GSC lines and we did not test all possible 
conditions: We neither used extreme condi-
tions, nor did we investigate the effects of very 
long treatment (>1 week). Even if the investiga-
tion of 20 GSC lines would have shown sub-
stantial effects in 1-2 GSC lines under extreme 
conditions, our major conclusion would have 
remained unchanged: A substantial proneural-
to-mesenchymal transformation triggered by 
chronic physiological metabolic changes is not 
common and therefore likely not relevant for 
the vast majority of patients.
In summary, our experiments did not provide 
any evidence in support of the concept post- 
ulating that the proneural-to-mesenchymal 
transformation induced by changes of the local 
metabolic microenviroment is common and 
relevant.
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